CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

CD19-targeted chimeric antigen receptor T (CAR T) cell therapy is a promising option to treat relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, the majority of CAR T-treated patients will eventually progress and require salvage treatment, for which there is no current standard....

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yun, Liu, Hui, Lu, Zheming, Lei, Wen, Zhang, Chaoting, Li, Ping, Liang, Aibin, Young, Ken H., Qian, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885572/
https://www.ncbi.nlm.nih.gov/pubmed/33593414
http://dx.doi.org/10.1186/s13045-021-01044-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885572/
https://www.ncbi.nlm.nih.gov/pubmed/33593414
http://dx.doi.org/10.1186/s13045-021-01044-y

Ejemplares similares